December 22, 2023 – Quidel Company has obtained 510(Ok) clearance from the U.S. Meals and Drug Administration for its modern Savanna PCR platform and Savanna HSV 1+2/VZV in vitro diagnostic take a look at for the detection and differentiation of Herpes simplex virus kind 1 (HSV-1), Herpes simplex virus kind 2 (HSV-2) and Varicella-zoster virus (VZV) nucleic acids remoted and purified from swabs obtained from samples of cutaneous or mucocutaneous lesions obtained from symptomatic sufferers.

The approval permits QuidelOrtho to commercialize and promote the Savanna multiplex molecular platform and the Savanna HSV 1+2/VZV take a look at to laboratories performing reasonable or excessive complexity diagnostic assessments in the US.

The Savanna multiplex molecular platform permits skilled prospects to research as much as 12 pathogens or targets, plus as much as 4 controls, from a single take a look at run in roughly 25 minutes, relying on the take a look at. Savanna is a completely built-in, sample-to-result, automated in vitro diagnostic platform that performs real-time polymerization chain response (“PCR”) testing utilizing the Savanna instrument and Savanna assay cartridges.

After inserting the customizable take a look at panel cartridge, the instrument performs pattern and reagent preparation, nucleic acid extraction and amplification, real-time detection of RNA or DNA goal sequence, and qualitative or quantitative end result interpretation from a wide range of pattern sorts. The Savanna platform is meant to help within the prognosis of associated ailments, in order that sufferers obtain the proper prognosis shortly and precisely.

The Savanna HSV 1+2/VZV take a look at panel is meant to help within the differential prognosis of infections with these viruses. Savanna will likely be accessible to skilled prospects from December 20, 2023.

Study extra